The US approach to biosimilars explained
The FDA’s draft guidance for biosimilars has provided some clarity for biosimilar applicants and innovator biologic companies. But lawyers say many questions remain
The guidance was released last week on the Federal Drug Adminsitration’s website, but has not yet been published in the Federal Register. The comment period will not begin until the Federal Register Notice is announced.
The United States paved...
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain FREE access to up to five free articles when you register now.